Patients taking Novo Nordisk's Wegovy obesity treatment maintained an average of 10% weight loss after four years, ...
Novo Nordisk's (NVO) obesity therapy Wegovy cut adverse kidney-related events by 22% in obese and overweight individuals in a ...
The results shed light on the long-term effects of Wegovy, and could boost Novo Nordisk’s case to insurers and governments to ...
Presented at this week’s European Congress on Obesity, the two studies also demonstrate that Novo Nordisk’s Wegovy ...
The data could potentially bolster Novo's case for Wegovy as it attempts to convince insurers and governments to cover the ...
Novo Nordisk's Wegovy treatment demonstrated sustained weight loss over four years, according to long-term study results ...
Researchers highlighted on Monday that certain genes may help identify patients with obesity who are most likely to respond ...
The data could go some way to convince insurers and governments to reimburse Wegovy. Read more at straitstimes.com.
Amid the growing popularity of drugs used for weight loss like Ozempic, Wegovy, Mounjaro and Zepbound, one question has ...
Novo Nordisk has blamed middlemen in the U.S. healthcare system for the high prices of its top-selling weight-loss drugs ...
A NEW weight loss drug could hijack the brain like a ‘Trojan horse’ to double weight loss. The drug could help the body to ...
Novo Nordisk (NVO) claims it retains only 60% of list price of weight loss drugs Ozempic and Wegovy after payments to pharma ...